In response to their book published in 2019, later revised in 2024, entitled 'The Age of Biopharmaceuticals Is Coming', Drs. Howard Lee and Siun Kim were interviewed by Korea Job World early this year, which has been posted on YouTube. This interview was primarily focused on biopharmaceuticals in terms of their differences in comparison with small molecule drugs and as to why they have become important recently. Drs. Lee and Kim also discussed what kinds of disciplines and technologies are critical to successfully develop a biopharmaceutical. A full video clip can be watched by clicking the link below. 

This summer, CCADD welcomes three interns-Kim Chanmin, Choi Yunjin, and Yoo Kyungwan -for the 2024 Summer Internship Program.

Kyungwan Yoo, a student at Kyung Hee University, earned his Bachelor’s degree in genetic engineering. He worked as an undergraduate researcher at the Kyung Hee University Regenerative Medicine Institute, focusing on creating cell-targeting treatments. Currently, he is interested in integrating biological science with artificial intelligence (AI) technology and applying it to drug development. Kyungwan applied for the 2024 CCADD Summer Internship Program to expand his knowledge of drug development in general, be it clinical trials, and/or utilizing medical big data. He also intends to gain practical experiences in applying programming languages to these domains.

Yunjin Choi has graduated from Stony Brook University with a Bachelor’s degree in mathematics. After graduating, Yunjin worked as a statistical analyst at the Biomedical Research Institute, Korea University Guro Hospital. She has mainly conducted retrospective studies on nephrology and neurology. For example, she published a paper entitled "Fasting glucose variability and risk of dementia in Parkinson's disease: a 9-year longitudinal follow-up study of a nationwide cohort", which examined the impact of fasting glucose variability on the risk of developing dementia in Parkinson's disease patients over a nine-year period. The study found that greater variability in fasting glucose levels was associated with a higher risk of dementia, further suggesting that stabilizing glucose levels might be beneficial for cognitive health in these patients. Besides being the first author of the study, she was also responsible for data analysis and interpretation, ensuring the accuracy and reliability of the study results. She also has the opportunity to learn how to draft and revise the manu and enhance its scientific merit. During this time, Yunjin developed an interest in Real-World Data (RWD), such as electronic medical records (EMR). She intends to pursue her interest while at CCADD.

Chanmin Kim is a Biological Engineering major at Kangwon National University. She became interested in developing new drugs while learning drug delivery systems. She also completed GMP training. After receiving the Excellence Award for designing smart healthcare products at Gachon University's DNA (Data, Network, AI) School Camp , she became interested in improving the efficiency of developing new drugs by applying data science and AI. Her goal is to become a researcher in the development of new drugs using AI. Through her 2024 CCADD summer internship program, she will pursue this goal.

We hope that during their summer internship, they will gain confidence in their field of study, learn how to study independently and explore new knowledge, and devote all their passion to gaining a deep understanding of drug development and regulatory science over the course of these two months.

The study "Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus," authored by Yesol Hong, Yoomin Jeon, Yoona Choi, Tae Kyu Chung, and Howard Lee, was published in the Diabetes Therapy on December 20, 2023. Conducted at Seoul National University Hospital (SNUH) in South Korea, this research by the CCADD team delved into the use of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM) treatment. The study, utilizing Real-World Data (RWD) from electronic medical records (EMR) from SNUH's a Common Data Model database, revealed improvements in HbA1c levels and a higher rate of patients achieving targeted HbA1c levels with SGLT2i therapy.

Furthermore, CCADD is dedicated to continuing its use of EMR-based RWD to generate important clinical evidence, particularly in areas where Randomized Controlled Trials (RCTs) may face limitations. This commitment underscores CCADD's role in advancing medical research and improving patient care through innovative data utilization.

Prof. Howard Lee gave a talk at the 17th JSCPT-KSCPT Joint Symposium, Kobe, Japan, on December 15, 2023. In his presentation entitled 'Real-World Data Analysis as a Clinical Pharmacologist: Experience and Some Thoughts', Prof. Lee. introduce the audience to the RWD research works CCADD has performed for the past 3 or so years, all of which have been published in reputable journals or under review shown below. Prof. Lee stressed, "With RWD landscape fast growing, clinical pharmacologists should leverage the potentials of RWD/RWE in drug development by furthering its scientific innovation!" 

Prof. Lee's speech was well received by the audience followed by a welcome reception by JSCPT colleagues, whom he and other delegates have not seen in person for the past three years because of the COVID-19 pandemic. The night was full of talking, drinking, and singing! Both teams promised to meet again next year in Jeju, Korea, for the Spring Conference of 2024 KSCPT.